itraconazole

New pathways to cancer therapyA novel oral formulation of itraconazole (SUBA-Itraconazole, HedgePath Pharmaceuticals) is providing dramatic benefit for patients with basal cell carcinoma nevus syndrome (BCCNS, also known as Gorlin syndrome) and with a favorable safety profile, according to a recent interim analysis of data collected in a phase IIb study.
Debate surfaces over preferred treatments for fungal meningitis outbreak